Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety assessment of adjuvanted vaccines: Methodological considerations.
Tavares Da Silva F, Di Pasquale A, Yarzabal JP, Garçon N. Tavares Da Silva F, et al. Among authors: garcon n. Hum Vaccin Immunother. 2015;11(7):1814-24. doi: 10.1080/21645515.2015.1043501. Hum Vaccin Immunother. 2015. PMID: 26029975 Free PMC article. Review.
Vaccine Adjuvants: from 1920 to 2015 and Beyond.
Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Di Pasquale A, et al. Among authors: garcon n. Vaccines (Basel). 2015 Apr 16;3(2):320-43. doi: 10.3390/vaccines3020320. Vaccines (Basel). 2015. PMID: 26343190 Free PMC article. Review.
Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N. Didierlaurent AM, et al. Among authors: garcon n. Expert Rev Vaccines. 2017 Jan;16(1):55-63. doi: 10.1080/14760584.2016.1213632. Epub 2016 Aug 2. Expert Rev Vaccines. 2017. PMID: 27448771 Review.
From discovery to licensure, the Adjuvant System story.
Garçon N, Di Pasquale A. Garçon N, et al. Hum Vaccin Immunother. 2017 Jan 2;13(1):19-33. doi: 10.1080/21645515.2016.1225635. Epub 2016 Sep 16. Hum Vaccin Immunother. 2017. PMID: 27636098 Free PMC article. Review.
Vaccine safety evaluation: Practical aspects in assessing benefits and risks.
Di Pasquale A, Bonanni P, Garçon N, Stanberry LR, El-Hodhod M, Tavares Da Silva F. Di Pasquale A, et al. Among authors: garcon n. Vaccine. 2016 Dec 20;34(52):6672-6680. doi: 10.1016/j.vaccine.2016.10.039. Epub 2016 Nov 8. Vaccine. 2016. PMID: 27836435 Free article. Review.
Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.
Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, Gabor JJ, Esen M, Hens A, Carletti I, Fissette L, Tavares Da Silva F, Burny W, Janssens M, Moris P, Didierlaurent AM, Van Der Most R, Garçon N, Van Belle P, Van Mechelen M. Leroux-Roels G, et al. Among authors: garcon n. Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25. Clin Immunol. 2016. PMID: 27236001 Free article. Clinical Trial.
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, Tavares Da Silva F, Rappuoli R, Garçon N, Innis BL. Cohet C, et al. Among authors: garcon n. Vaccine. 2019 May 21;37(23):3006-3021. doi: 10.1016/j.vaccine.2019.04.048. Epub 2019 Apr 25. Vaccine. 2019. PMID: 31031030 Free article. Review.
Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
Coccia M, Collignon C, Hervé C, Chalon A, Welsby I, Detienne S, van Helden MJ, Dutta S, Genito CJ, Waters NC, Deun KV, Smilde AK, Berg RAVD, Franco D, Bourguignon P, Morel S, Garçon N, Lambrecht BN, Goriely S, Most RV, Didierlaurent AM. Coccia M, et al. Among authors: garcon n. NPJ Vaccines. 2017 Sep 8;2:25. doi: 10.1038/s41541-017-0027-3. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263880 Free PMC article.
74 results